Net (Loss)/Income Per Share

3 Months Ended

Mar. 31, 2023

Net (Loss)/Income Per Share

Net (Loss)/Income Per Share

4. Net (Loss)/Income Per Share

The following table sets forth the computation of basic and diluted net (loss)/income per share for the three months ended March 31, 2023, and 2022 (in thousands, except number of shares):

	Three months ended March 31,
	2023			2022
Numerator:
Net (loss)/income	$	(18,223)	$	2,574
Net loss attributable to noncontrolling interest		43		22
Net (loss)/income attributable to Vaccitech shareholders	$	(18,180)	$	2,596
Denominator:
Weighted-average ordinary shares outstanding, basic		38,013,399		37,191,022
Effect of dilutive stock options		—		1,155,646
Weighted-average ordinary shares outstanding, diluted		38,013,399		38,346,668
Net (loss)/income per share attributable to ordinary shareholders, basic	$	(0.48)	$	0.070
Net (loss)/income per share attributable to ordinary shareholders, diluted	$	(0.48)	$	0.068

For the three month period ended March 31, 2023 and 2022, 4,134,286 and 2,014,204 potential ordinary shares issuable for stock options, respectively, were excluded from the computation of diluted weighted-average shares outstanding because including them would have had an anti-dilutive effect.